Welcome to our dedicated page for Hyperion DeFi SEC filings (Ticker: HYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hyperion DeFi, Inc. (NASDAQ: HYPD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. Hyperion DeFi’s filings describe its evolution from an ophthalmic technology company into a Hyperliquid-native DeFi business that builds and deploys a long-term strategic treasury of HYPE, the native token of the Hyperliquid blockchain, while continuing development of its Optejet User Filled Device.
Investors can review Form 8-K current reports that detail material events such as at-the-market equity program amendments, Sales Agreements with investment banks, HAUS agreements with DeFi partners, and the Joint Validator Operators’ Agreement for the Kinetiq × Hyperion validator node. Other 8-K filings describe leadership changes, including appointments of key executives, and press releases furnishing quarterly financial results and investor presentations.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically provide a broader view of Hyperion DeFi’s business model, including its digital asset treasury strategy, revenue components such as staking rewards, validator commissions, yield enhancement, DeFi monetization, and ecosystem rewards, as well as its ongoing life sciences activities around the Optejet User Filled Device. Proxy statements on Schedule 14A can offer additional detail on governance, board composition, and executive compensation.
On Stock Titan, these filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight key points from lengthy documents, helping readers understand how new agreements, capital raises, or digital asset strategies may affect Hyperion DeFi’s operations and risk profile. Users can also review Form 4 insider transaction reports to see how directors and officers are trading HYPD shares, and use AI explanations to interpret complex disclosures without wading through full-text filings.
Hyperion DeFi, Inc. (HYPD) filed an amended shelf registration describing a resale offering by selling securityholders of up to 50,770,667 shares of Common Stock, which includes shares issuable on conversion of Series A Preferred Stock, in-kind dividends on that preferred, and shares issuable upon exercise of outstanding Warrants. The company would not receive proceeds from secondary sales, but would receive approximately $107.4 million only if the Warrants are exercised for cash in full; any such proceeds would be used for working capital and to build the company’s HYPE token reserve. The prospectus reiterates Nasdaq listing under ticker HYPD, outstanding equity awards and warrants, and discloses a broad set of risks tied to HYPE token volatility, blockchain developments, regulatory and macroeconomic factors. The filing also details selling holders, beneficial ownership limitations, and incorporation by reference of prior SEC reports.
Prospectus supplement amendment discloses equity and token-related dilution details and enumerates extensive risks tied to the companys crypto operations. The filing lists outstanding and reserved equity instruments including warrants, options and restricted stock units: warrants to purchase 33,820,785 shares (weighted average exercise price $3.54 as of Sept 10, 2025), options covering 51,936 shares (weighted average exercise price $222.61 as of Sept 10, 2025), restricted stock units of 386,651 shares, and 5,001,777 shares reserved for future issuance under incentive plans, plus 500,000 inducement RSUs.
The document lists risk drivers for HYPE and Hyperliquid including regulatory, market, technological and macroeconomic risks, potential liquidity and custodial counterparty failures, blockchain protocol changes, transaction congestion and decreases in user confidence. The amendment incorporates by reference prior SEC filings and recent 8-K/Form 10 filings.
Prospectus supplement amendment discloses equity and token-related dilution details and enumerates extensive risks tied to the companys crypto operations. The filing lists outstanding and reserved equity instruments including warrants, options and restricted stock units: warrants to purchase 33,820,785 shares (weighted average exercise price $3.54 as of Sept 10, 2025), options covering 51,936 shares (weighted average exercise price $222.61 as of Sept 10, 2025), restricted stock units of 386,651 shares, and 5,001,777 shares reserved for future issuance under incentive plans, plus 500,000 inducement RSUs.
The document lists risk drivers for HYPE and Hyperliquid including regulatory, market, technological and macroeconomic risks, potential liquidity and custodial counterparty failures, blockchain protocol changes, transaction congestion and decreases in user confidence. The amendment incorporates by reference prior SEC filings and recent 8-K/Form 10 filings.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Hyperion DeFi, Inc. disclosed an amendment to its sales agreement with Chardan Capital Markets, LLC. The filing lists an Amendment No. 1 to the Amended and Restated Sales Agreement, and includes a legal opinion and consent from Covington & Burling LLP plus an interactive cover page data file. The document does not provide transaction amounts, share counts, or other financial metrics, so the practical effect on capital raising or dilution is not specified.
Amendment No. 6 to a Schedule 13D discloses the current beneficial ownership positions of several related Avenue/GL reporting persons in Hyperion DeFi, Inc. The funds directly hold 96,049 and 144,075 shares respectively, while Avenue Capital Management II, L.P. reports sole voting and dispositive power over 240,124 shares in total, representing 4.2% of the outstanding common stock. The filing notes an aggregate 9.99% ownership blocker that limits beneficial ownership (which can be increased to 19.99% with notice), and excludes an aggregate of 250,000 warrants exercisable at $4.00 per share from the reported percentages. The Amendment states it is being filed to report sales of common stock and resulting changes in the reporting persons' beneficial ownership. Contact and issuer principal office details are provided for notice purposes.
Amendment No. 6 to a Schedule 13D discloses the current beneficial ownership positions of several related Avenue/GL reporting persons in Hyperion DeFi, Inc. The funds directly hold 96,049 and 144,075 shares respectively, while Avenue Capital Management II, L.P. reports sole voting and dispositive power over 240,124 shares in total, representing 4.2% of the outstanding common stock. The filing notes an aggregate 9.99% ownership blocker that limits beneficial ownership (which can be increased to 19.99% with notice), and excludes an aggregate of 250,000 warrants exercisable at $4.00 per share from the reported percentages. The Amendment states it is being filed to report sales of common stock and resulting changes in the reporting persons' beneficial ownership. Contact and issuer principal office details are provided for notice purposes.
Amendment No. 5 to a Schedule 13D reports the current holdings and arrangements of several Avenue-related reporting persons with respect to Hyperion DeFi, Inc. (HYPD) common stock. The filing lists the issuer's principal office in Laguna Hills, California, and states the update reflects a change in beneficial ownership due to an increase in the issuer's outstanding shares. The reported share counts and percentages are measured against 5,694,659 shares outstanding as of August 11, 2025. Avenue Venture Opportunities Fund holds 141,716 shares (2.5%), Avenue Venture Opportunities Fund II holds 212,575 shares (3.7%), and Avenue Capital Management II reports sole voting and dispositive power over 354,291 shares (6.2%). The Reporting Persons note a 9.99% blocker (electable up to 19.99% with 61 days' notice) that excludes shares issuable on warrants; specific warrant exclusions are disclosed for the Funds.
Amendment No. 5 to a Schedule 13D reports the current holdings and arrangements of several Avenue-related reporting persons with respect to Hyperion DeFi, Inc. (HYPD) common stock. The filing lists the issuer's principal office in Laguna Hills, California, and states the update reflects a change in beneficial ownership due to an increase in the issuer's outstanding shares. The reported share counts and percentages are measured against 5,694,659 shares outstanding as of August 11, 2025. Avenue Venture Opportunities Fund holds 141,716 shares (2.5%), Avenue Venture Opportunities Fund II holds 212,575 shares (3.7%), and Avenue Capital Management II reports sole voting and dispositive power over 354,291 shares (6.2%). The Reporting Persons note a 9.99% blocker (electable up to 19.99% with 61 days' notice) that excludes shares issuable on warrants; specific warrant exclusions are disclosed for the Funds.
Hyperion DeFi director Happy David Walters received 50,000 restricted stock units (RSUs) reported as a non‑derivative acquisition on 09/08/2025. The RSUs are recorded at $0 and are beneficially owned directly following the grant. The award vests in three tranches: 25,000 RSUs on March 31, 2026; 12,500 RSUs on August 16, 2026; and 12,500 RSUs on November 16, 2026. The RSUs accelerate and vest in full if the company undergoes a change in control or if the director’s board service is terminated for reasons other than a voluntary resignation.
Hyperion DeFi, Inc. director reports no share ownership. Walters Happy David, a director of Hyperion DeFi, Inc. (HYPD), filed an initial Form 3 beneficial ownership report for his role with the company. The filing indicates that he does not beneficially own any non-derivative or derivative securities of Hyperion DeFi, Inc., and no transactions are reported. The remarks section explicitly states that no securities are beneficially owned, confirming a zero-ownership position at the time of this filing.
Hyperion DeFi, Inc. reports that Nasdaq staff notified the company on September 2, 2025 that it has regained compliance with the Nasdaq minimum $2,500,000 stockholders’ equity requirement for continued listing under Listing Rule 5550(b)(1). This follows an earlier notice in April 2025 that its reported equity was below that threshold.
On the same date, Chief Executive Officer Michael Rowe informed the board of his intent to resign. Until his resignation becomes effective, Chief Investment Officer and director Hyunsu Jung will serve as Interim Chief Executive Officer, Principal Financial Officer, Treasurer, and Secretary, working with Mr. Rowe on a smooth transition.
The board also expanded its size to six members and appointed Happy Walters as a director, effective immediately, with a term through the 2026 annual meeting. In connection with his board service, Mr. Walters received 50,000 restricted stock units that vest in tranches on March 31, 2026, August 16, 2026, and November 16, 2026, or fully upon certain change-in-control or non-voluntary separation events.
Insider grant and ownership update: On 08/18/2025 Hyunsu Jung, a director and Chief Investment Officer of Hyperion DeFi, Inc. (HYPD), was granted 1,000,000 shares of common stock at a reported price of $0. The Form 4 shows Jung beneficially owns 1,500,000 shares following the reported transaction. The grant is performance-contingent: 500,000 shares vest if the issuer reaches a market capitalization of $150,000,000 and the remaining 500,000 shares vest if market capitalization reaches $500,000,000.
Rachel Jacobson, a director of Hyperion DeFi, Inc. (HYPD), was granted 50,000 restricted stock units (RSUs) on 08/18/2025. The RSUs are non‑cash awards that vest in three tranches: 25,000 on December 15, 2025; 12,500 on May 26, 2026; and 12,500 on August 16, 2026. All RSUs will vest immediately if a defined Corporate Transaction occurs or if Ms. Jacobson’s board service ends for any reason other than her voluntary resignation. After the grant, Ms. Jacobson beneficially owns 56,301 shares. The filing is a Form 4 disclosure signed and dated 08/20/2025.